SAB Biotherapeutics (SABSW) Operating Income (2021 - 2025)
Historic Operating Income for SAB Biotherapeutics (SABSW) over the last 5 years, with Q3 2025 value amounting to -$12.7 million.
- SAB Biotherapeutics' Operating Income fell 1211.03% to -$12.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$43.2 million, marking a year-over-year increase of 1657.83%. This contributed to the annual value of -$42.9 million for FY2024, which is 1269.9% down from last year.
- Latest data reveals that SAB Biotherapeutics reported Operating Income of -$12.7 million as of Q3 2025, which was down 1211.03% from -$9.7 million recorded in Q2 2025.
- In the past 5 years, SAB Biotherapeutics' Operating Income registered a high of $813924.0 during Q1 2021, and its lowest value of -$18.9 million during Q4 2023.
- In the last 5 years, SAB Biotherapeutics' Operating Income had a median value of -$7.8 million in 2022 and averaged -$8.2 million.
- Per our database at Business Quant, SAB Biotherapeutics' Operating Income crashed by 92407.44% in 2022 and then skyrocketed by 4696.96% in 2024.
- Quarter analysis of 5 years shows SAB Biotherapeutics' Operating Income stood at -$7.3 million in 2021, then decreased by 7.02% to -$7.9 million in 2022, then tumbled by 140.12% to -$18.9 million in 2023, then surged by 46.97% to -$10.0 million in 2024, then fell by 26.68% to -$12.7 million in 2025.
- Its Operating Income was -$12.7 million in Q3 2025, compared to -$9.7 million in Q2 2025 and -$10.8 million in Q1 2025.